TScan Therapeutics (TCRX) Free Cash Flow (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Free Cash Flow data on file, last reported at -$24.3 million in Q1 2026.

• On a quarterly basis, Free Cash Flow rose 37.75% year-over-year to -$24.3 million in Q1 2026; TTM through Mar 2026 was -$120.6 million, a 2.61% increase from a year earlier, with the FY2025 full-year figure at -$135.3 million, down 18.04% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$24.3 million, up from -$32.0 million in the prior quarter.
• Over the last five years, Free Cash Flow for TCRX reached as high as $7.8 million in Q3 2023 and fell as low as -$39.1 million in Q1 2025.
• Historically, Free Cash Flow has averaged -$23.7 million across 5 years, with a median of -$24.3 million in 2026.
• Across the five-year window, Free Cash Flow surged 151.23% in 2023 and slumped 477.37% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$15.9 million in 2022, then plunged by 49.38% to -$23.7 million in 2023, then dropped by 19.29% to -$28.3 million in 2024, then retreated by 12.92% to -$32.0 million in 2025, then increased by 23.81% to -$24.3 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$24.3 million in Q1 2026, -$32.0 million in Q4 2025, and -$31.6 million in Q3 2025.